Sapna P. Patel, Alexander J. Lazar, Nicholas E. Papadopoulos, Ping Liu, Jeffrey R. Infante, Michelle R. Glass, Carol S. Vaughn, Patricia M. LoRusso, Roger B. Cohen, Michael A. Davies and Kevin B. Kim Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma Cancer 119
Article first published online: 12 SEP 2012 | DOI: 10.1002/cncr.27790
The authors analyze tumor mutation status and response to therapy in patients with melanoma who were enrolled on a phase 1 study of selumetinib-containing regimens. The results demonstrate that patients who have melanoma with a v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation have a considerably better clinical benefit from selumetinib-containing regimens than those without a BRAF mutation.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field